Physician profile
Mitchell S Norfleet
NPI 1225040900
$1,464.72
in general payments reported to CMS, 2019-2025
28 companies · $434 in 2025
The $434 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $286 · 2022: $129 · 2023: $348 · 2024: $268 · 2025: $434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,049.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $250.62 | 2021-2025 | |
| Novo Nordisk INC | $163.74 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $133.31 | 2021-2025 | Evenity, Prolia |
| Aimmune Therapeutics, INC. | $97.54 | 2024 | |
| Itamar Medical INC | $96.25 | 2022 | |
| Pfizer INC. | $88.55 | 2021-2025 | |
| Inspire Medical Systems, INC. | $65.04 | 2025 | Inspire |
| Phathom Pharmaceuticals, INC. | $57.48 | 2025 | Voquezna |
| Lilly USA, LLC | $49.08 | 2021-2025 | Mounjaro |
| Vanda Pharmaceuticals INC. | $45.02 | 2024-2025 | Fanapt, Hetlioz |
| Astrazeneca Pharmaceuticals LP | $43.02 | 2023-2025 | Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.74 | 2021-2023 | |
| Actelion Pharmaceuticals US, INC. | $31.93 | 2023 | Opsumit, Uptravi |
| Heartflow, INC. | $28.57 | 2025 | |
| Janssen Pharmaceuticals, INC | $28.42 | 2023 | Invega Sustenna |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $27.08 | 2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.08 | 2025 | Caplyta |
| Bausch Health US, LLC | $23.69 | 2023 | Wellbutrin, Aplenzin |
| Sanofi-Aventis U.S. LLC | $22.39 | 2024 | |
| Organon LLC | $21.41 | 2024 | |
| Abbott Laboratories | $20.36 | 2024 | Freestyle Libre 3 |
| Tactile Systems Technology INC | $17.82 | 2024 | Entre Plus, Flexitouch Plus |
| Ardelyx, INC. | $17.53 | 2025 | Ibsrela |
| Glaxosmithkline, LLC. | $16.44 | 2023 | Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $15.39 | 2021 | |
| Exact Sciences Corporation | $15.23 | 2024 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $13.94 | 2021 | |
| Astellas Pharma US INC | $13.05 | 2023 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Norfleet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.